Distribution of AAV-TK following intracranial convection-enhanced delivery into rats

被引:57
作者
Cunningham, J
Oiwa, Y
Nagy, D
Podsakoff, G
Colosi, P
Bankiewicz, KS
机构
[1] NINDS, Mol Therapeut Sect, LMMN, NIH, Bethesda, MD 20892 USA
[2] Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Funct Imaging, Berkeley, CA 94720 USA
关键词
adeno-associated virus; thymidine kinase (ACC-TK); intracranial delivery; convection-enhanced delivery;
D O I
10.1177/096368970000900504
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Adeno-associated virus (AAV)-based vectors are being tested in animal models as viable treatments for glioma and neurodegenerative disease and could potentially be employed to target a variety of central nervous system disorders. The relationship between dose of injected vector and its resulting distribution in brain tissue has not been previously reported nor has the most efficient method of delivery been determined. Hen we report that convection-enhanced delivery (CED) of 2.5 x 10(8), 2.5 x 10(9), or 2.5 x 10(10) particles of AAV-thymidine kinase (AAV-TK) into rat brain revealed a clear dose response. In the high-dose group, a volume of 300 mm(3) of brain tissue was partially transduced. Results showed that infusion pump and subcutaneous osmotic pumps were both capable of delivering vector via CED and that total particle number was the most important determining factor in obtaining efficient expression. Results further showed differences in histopathology between the delivery groups. While administration of vector using. infusion pump had relatively benign effects, the use of osmotic pumps resulted in notable toxicity to the surrounding brain tissue. To determine tissue distribution of vector following intracranial delivery, PCR analysis was performed on tissues from rats that received high doses of AAV-TK. three weeks following CED, vector could be detected in both hemispheres of the brain, spinal cord, spleen, and kidney.
引用
收藏
页码:585 / 594
页数:10
相关论文
共 28 条
[1]  
Bankiewicz K. S., 1996, Society for Neuroscience Abstracts, V22, P768
[2]   Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease [J].
Bankiewicz, KS ;
Leff, SE ;
Nagy, D ;
Jungles, S ;
Rokovich, J ;
Spratt, K ;
Cohen, L ;
Libonati, M ;
Snyder, RO ;
Mandel, RJ .
EXPERIMENTAL NEUROLOGY, 1997, 144 (01) :147-156
[3]   Selective and rapid uptake of adeno-associated virus type 2 in brain [J].
Bartlett, JS ;
Samulski, RJ ;
McCown, TJ .
HUMAN GENE THERAPY, 1998, 9 (08) :1181-1186
[4]   Gene transfer to rodent brain with recombinant adenoviral vectors: Effects of infusion parameters, infectious titer, and virus concentration on transduction volume [J].
Betz, AL ;
Shakui, P ;
Davidson, BL .
EXPERIMENTAL NEUROLOGY, 1998, 150 (01) :136-142
[5]   CONVECTION-ENHANCED DELIVERY OF MACROMOLECULES IN THE BRAIN [J].
BOBO, RH ;
LASKE, DW ;
AKBASAK, A ;
MORRISON, PF ;
DEDRICK, RL ;
OLDFIELD, EH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2076-2080
[6]  
Byrnes AP, 1996, J NEUROSCI, V16, P3045
[7]  
Conrad CK, 1996, GENE THER, V3, P658
[8]   GENE-EXPRESSION FROM RECOMBINANT VIRAL VECTORS IN THE CENTRAL-NERVOUS-SYSTEM AFTER BLOOD-BRAIN-BARRIER DISRUPTION [J].
DORAN, SE ;
REN, XD ;
BETZ, AL ;
PAGEL, MA ;
NEUWELT, EA ;
ROESSLER, BJ ;
DAVIDSON, BL .
NEUROSURGERY, 1995, 36 (05) :965-970
[9]  
Du B, 1996, GENE THER, V3, P254
[10]   STABLE IN-VIVO EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR WITH AN ADENOASSOCIATED VIRUS VECTOR [J].
FLOTTE, TR ;
AFIONE, SA ;
CONRAD, C ;
MCGRATH, SA ;
SOLOW, R ;
OKA, H ;
ZEITLIN, PL ;
GUGGINO, WB ;
CARTER, BJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10613-10617